$5.59
+0.10 (+1.82%)
Open$5.51
Previous Close$5.49
Day High$5.60
Day Low$5.46
52W High$11.54
52W Low$3.75
Volume—
Avg Volume28.0K
Market Cap116.10M
P/E Ratio—
EPS$-1.37
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+486.2% upside
Current
$5.59
$5.59
Target
$32.77
$32.77
$27.05
$32.77 avg
$46.02
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.36M | 16.49M | 13.84M |
| Net Income | -919,800 | -1,097,385 | -862,011 |
| Profit Margin | -5.6% | -6.7% | -6.2% |
| EBITDA | -1,433,447 | -1,263,705 | -1,141,891 |
| Free Cash Flow | -1,064,720 | -1,173,966 | -726,945 |
| Rev Growth | +3.8% | -10.0% | -5.2% |
| Debt/Equity | 1.22 | 1.29 | 1.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |